A Prospective, Open-Label, Multicenter, Real-World Study to Evaluate the Efficacy and Safety of Tunlametinib in Patients With NRAS-Mutant Advanced Melanoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Aged ≥18 years (inclusive), male or female;
• Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
• Prior genetic testing results showing positive NRAS mutation;
• Patients who have failed prior anti-PD-1/PD-L1 therapy;
• Able to take oral medications;
• Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.
Locations
Other Locations
China
Fudan University Shanghai Cancer Center
RECRUITING
Shanghai
Contact Information
Primary
Yu Wang
neck130@sina.com
86-021-64175590
Time Frame
Start Date: 2026-01-28
Estimated Completion Date: 2029-01-31
Participants
Target number of participants: 110
Treatments
Experimental: Tunlametinib
Related Therapeutic Areas
Sponsors
Leads: Fudan University